文献速递睡眠呼吸障碍

舌下神经刺激与阻塞性睡眠呼吸暂停患者长期患者报告结局改善及与持续气道正压的比较

Association of Hypoglossal Nerve Stimulation With Improvements in Long-term, Patient-Reported Outcomes and Comparison With Positive Airway Pressure for Patients With Obstructive Sleep Apnea.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2022-01-01

这项回顾性队列研究纳入85例接受舌下神经刺激(HNS)和217例接受持续气道正压(PAP)的阻塞性睡眠呼吸暂停(OSA)患者,按3:1匹配。HNS组PHQ-9评分改善优于PAP组(最小二乘均值-4.06 vs -2.58,均数差-1.48)。HNS后1年患者报告结局持续改善,与PAP治疗3个月时相当。

要点

  • HNS组PHQ-9评分改善优于PAP组,均数差-1.48(95%CI,-2.78至-0.19)。
  • HNS后1年ESS、FOSQ、PHQ-9和ISI均见持续改善。
  • HNS后1年达到临床意义改善的比例:ESS 60.7%、FOSQ 55.0%、PHQ-9 30.4%、ISI 44.0%。

核心结论

  • 在OSA患者中,HNS后1年患者报告结局持续改善,与PAP治疗3个月时相当。
  • 这些发现提示HNS是改善OSA患者失眠和抑郁的可行治疗方法。

研究设计与样本

  • 回顾性队列研究,使用克利夫兰诊所OSA患者数据。
  • HNS组85例(2015年11月1日至2018年9月31日),PAP组217例(2010年1月1日至2014年12月31日)。
  • 按年龄、BMI、性别和AHI以3:1比例匹配PAP:HNS。
  • 数据于2020年3月26日至2021年9月9日分析。

主要发现

  • HNS组 vs PAP组PHQ-9评分最小二乘均值变化:-4.06(95%CI,-5.34至-2.79)vs -2.58(95%CI,-3.35至-1.82),均数差-1.48(95%CI,-2.78至-0.19)。
  • ESS、FOSQ和ISI评分改善程度两组相当。
  • 达到临床意义改善的比例:ESS为HNS组42/65例(64.6%)vs PAP组118/217例(54.5%);FOSQ为HNS组29/49例(59.2%)vs PAP组67/217例(30.9%);PHQ-9为HNS组14/48例(29.2%)vs PAP组53/217例(24.4%);ISI为HNS组23/49例(46.9%)vs PAP组79/217例(36.4%)。
  • HNS后1年评估时达到有意义改善的比例:ESS为17/28例(60.7%),FOSQ为11/20例(55.0%),PHQ-9为7/23例(30.4%),ISI为11/25例(44.0%)。

临床怎么用

  • 作者认为HNS是改善OSA患者失眠和抑郁的可行治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypoglossal nerve stimulation (HNS) and positive airway pressure (PAP) have been shown to improve patient-reported outcomes (PROs) in obstructive sleep apnea (OSA). However, to our knowledge, there are no data that compare change in PROs between HNS and PAP or that indicate whether HNS improves comorbid insomnia or depression in the long term. OBJECTIVES: To determine whether HNS is associated with improvements in patient-reported sleepiness, insomnia, and depression in the long term and to compare the respective associations of HNS and PAP with improved PROs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from patients treated at the Cleveland Clinic for OSA. Participants received either HNS (referred sample) from November 1, 2015, to September 31, 2018, or PAP (previous cohort) from January 1, 2010, to December 31, 2014, for OSA. Patients were matched 3:1 for PAP:HNS based on age, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), sex, and apnea hypopnea index (AHI). Data were collected at baseline and at prespecified follow-up points. Data were analyzed from March 26, 2020, to September 9, 2021. EXPOSURES: Treatment with HNS vs PAP. MAIN OUTCOMES AND MEASURES: Data collected included AHI and Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ), Insomnia Severity Index (ISI), and Patient Health Questionnaire-9 (PHQ-9; depression) scores. RESULTS: Among 85 patients receiving HNS (mean [SD] age, 62.8 [9.5] years; 59 men [69.4%]; 77 White patients [90.6%]; mean [SD] BMI, 28.8 [3.1]), compared with 217 matched patients receiving PAP (mean [SD] age, 62.1 [9.9] years; 157 men [72.4%]; 173 White patients [81.2%]; mean [SD] BMI, 29.5 [3.1]) included in the analysis, significant improvements were seen in PHQ-9 scores for HNS vs PAP (least square means, -4.06 [95% CI, -5.34 to -2.79] vs -2.58 [95% CI, -3.35 to -1.82]; mean difference, -1.48 [95% CI, -2.78 to -0.19]) with comparable improvements in ESS, FOSQ, and ISI scores. Clinically meaningful differences were observed in 42 of 65 HNS group patients (64.6%) vs 118 PAP group patients (54.5%) for ESS scores, 29 of 49 HNS group patients (59.2%) vs 67 of 217 PAP group patients (30.9%) for FOSQ scores, 14 of 48 HNS group patients (29.2%) vs 53 of 217 PAP group patients (24.4%) for PHQ-9 scores, and 23 of 49 HNS group patients (46.9%) vs 79 of 217 PAP group patients (36.4%) for ISI scores. At the 1-year post-HNS assessment, meaningful improvements were seen in 17 of 28 patients (60.7%) for ESS scores, 11 of 20 patients (55.0%) for FOSQ scores, 7 of 23 patients (30.4%) for PHQ-9 scores, and 11 of 25 patients (44.0%) for ISI scores. CONCLUSIONS AND RELEVANCE: In this cohort study of patients with OSA, sustained improvements in PROs were observed 1 year after HNS and were comparable to those for PAP at 3 months. These findings suggest that HNS is a viable treatment for improving insomnia and depression in patients with OSA.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Pascoe M, Wang L, Aylor J, et al. Association of Hypoglossal Nerve Stimulation With Improvements in Long-term, Patient-Reported Outcomes and Comparison With Positive Airway Pressure for Patients With Obstructive Sleep Apnea. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 34762105. doi:10.1001/jamaoto.2021.2245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。